Long term follow-up of Behcet's syndrome patients treated with cyclophosphamide

Gurcan M., Esatoglu S. N., HAMURYUDAN V., Saygin D., UĞURLU S., SEYAHİ E., ...Daha Fazla

RHEUMATOLOGY, cilt.59, sa.9, ss.2264-2271, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 59 Sayı: 9
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1093/rheumatology/kez598
  • Dergi Adı: RHEUMATOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CINAHL, EMBASE, International Pharmaceutical Abstracts, MEDLINE
  • Sayfa Sayıları: ss.2264-2271
  • İstanbul Üniversitesi Adresli: Evet

Özet

Objectives. CYC remains an important treatment option for Behcet's syndrome (BS) patients with life-threatening manifestations. However, adverse events may occur with CYC and this has led to increased use of biologic agents in other vasculitides. We investigated short and long term adverse events associated with CYC use in BS patients.